Mindfulness-Based Cognitive Therapy Intervention for the Treatment of Late-Life Depression and Anxiety Symptoms in Primary Care: A Randomized Controlled Trial

2019 ◽  
Vol 88 (4) ◽  
pp. 254-256 ◽  
Author(s):  
S. Gabriela Torres-Platas ◽  
Sophia Escobar ◽  
Claudia Belliveau ◽  
Joyce Wu ◽  
Neeti Sasi ◽  
...  
Keyword(s):  
Primary Care ◽  
Randomized Controlled Trial ◽  
Cognitive Therapy ◽  
Controlled Trial ◽  
Late Life ◽  
Anxiety Symptoms ◽  
Depression And Anxiety ◽  
Late Life Depression ◽  
Randomized Controlled ◽  
Therapy Intervention

Collaborative care for primary care treatment of late‐life depression in Singapore: Randomized controlled trial

2020 ◽  
Vol 35 (10) ◽  
pp. 1171-1180
Author(s):  
Tze Pin Ng ◽  
Ma S. Z. Nyunt ◽  
Liang Feng ◽  
Rajeev Kumar ◽  
Calvin S. L. Fones ◽  
...  
Keyword(s):  
Primary Care ◽  
Randomized Controlled Trial ◽  
Collaborative Care ◽  
Controlled Trial ◽  
Late Life ◽  
Late Life Depression ◽  
Randomized Controlled ◽  
Care Treatment

scholarly journals Behavioural activation by mental health nurses for late-life depression in primary care: a randomized controlled trial

2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Noortje Janssen ◽  
Marcus J.H. Huibers ◽  
Peter Lucassen ◽  
Richard Oude Voshaar ◽  
Harm van Marwijk ◽  
...  
Keyword(s):  
Mental Health ◽  
Primary Care ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Late Life ◽  
Behavioural Activation ◽  
Late Life Depression ◽  
Mental Health Nurses ◽  
Randomized Controlled

scholarly journals Sahaj Samadhi meditation vs a Health Enhancement Program in improving late-life depression severity and executive function: study protocol for a two-site, randomized controlled trial

Trials ◽  
2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Stephen Benjamin Peckham ◽  
Emily Ionson ◽  
Marouane Nassim ◽  
Kevin Ojha ◽  
Lena Palaniyappan ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Executive Functioning ◽  
Controlled Trial ◽  
Late Life ◽  
Care Providers ◽  
Depression Severity ◽  
Late Life Depression ◽  
Randomized Controlled ◽  
Increased Risk ◽  
Augmentation Strategy

Abstract Background Recent estimates suggest an 11% prevalence of current late-life depression (LLD) and a lifetime prevalence of 16–20%. LLD leads to cognitive disturbance as well as a nearly two to three times increased risk of dementia. We conducted a recent randomized controlled trial (RCT) which demonstrated that Sahaj Samadhi meditation (SSM), an easy-to-implement, meditation-based augmentation strategy, led to higher rates of symptom remission when compared to treatment as usual (40.0 vs 16.3%; odds ratio, 3.36; 95% CI 1.06–10.64; p = 0.040). Here we present a protocol describing a two-site, blinded, RCT, comparing an SSM arm to an active-control arm – a Health Enhancement Program (HEP) intervention – in their ability to reduce depressive symptoms and improve executive functioning, among several other exploratory outcomes. Methods/design One hundred and ninety-two (n = 192) participants with LLD will be recruited at two sites (London, ON, Canada, and Montreal, QC, Canada). Participants will undergo stratified randomization with regards to site and the presence of treatment-resistant-LLD (TR-LLD) or not, to either SSM or HEP. We will assess change in (1) depression severity using the Hamilton Depression Rating Scale (HAM-D), (2) executive functioning, and (3) other exploratory physiological and mood-based measures, at baseline (0 weeks), post intervention (12 weeks), and 26 weeks after baseline. Raters, clinicians, and care providers will be blinded to group allocation while participants will be blinded to the study hypotheses. Discussion This study should more definitively assess whether SSM can be used as an augmentation strategy in routine clinical care for patients suffering from LLD and TR-LLD. If the effects of SSM are significantly better than HEP, it will offer support for the routine use of this intervention to manage LLD/TR-LLD and comorbid declines in executive dysfunction. The results of this study could also inform whether SSM can improve/prevent cognitive decline in LLD. Trial registration ClinicalTrials.gov, ID: NCT03564041. Registered on 20 June 2018.

Sign in / Sign up

Export Citation Format

Share Document